Basel Medical Group Ltd (NASDAQ:BMGL) Stock Short Interest Falls 92.9%

Basel Medical Group Ltd (NASDAQ:BMGL) saw a large decrease in short interest in September. As of September 30th, there was short interest totaling 11,310 shares, a decrease of 92.9% from the September 15th total of 159,585 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily volume of 57,193 shares, the days-to-cover ratio is currently 0.2 days.

Basel Medical Group Stock Performance

BMGL stock traded up $0.15 during mid-day trading on Friday, hitting $3.75. The company had a trading volume of 104,006 shares, compared to its average volume of 199,723. Basel Medical Group has a 12 month low of $2.56 and a 12 month high of $21.72. The stock’s fifty day moving average price is $4.67 and its two-hundred day moving average price is $6.26.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Basel Medical Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Basel Medical Group

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.